Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

HIV Infection

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 78 articles: HTML format

Single Articles

September 2024
1. SHIN Y, Park CM, Kim D-E, Kim S, et al
   Discovery of new acetamide derivatives of 5-indole-1,3,4-oxadiazol-2-thiol as inhibitors of HIV-1 Tat-mediated viral transcription.
   Antimicrob Agents Chemother. 2024 Sep 4:e0064324. doi: 10.1128/aac.00643.
   PubMed     Abstract available
   
   
   
2. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
   Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
   Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
   PubMed     Abstract available
   
   
   August 2024
3. ZANG X, Ankrom W, Kraft WK, Vargo R, et al
   Intracellular islatravir-triphosphate half-life supports extended dosing intervals.
   Antimicrob Agents Chemother. 2024 Aug 6:e0045824. doi: 10.1128/aac.00458.
   PubMed     Abstract available
   
   
   July 2024
4. BAE J, Tantawy M, Gong Y, Langaee T, et al
   Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
   Antimicrob Agents Chemother. 2024 Jul 30:e0054924. doi: 10.1128/aac.00549.
   PubMed     Abstract available
   
   
   
5. SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al
   Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
   Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354.
   PubMed     Abstract available
   
   
   
6. GIGANTE V, Alm RA, Melchiorri D, Rocke T, et al
   Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
   Antimicrob Agents Chemother. 2024 Jul 15:e0053524. doi: 10.1128/aac.00535.
   PubMed     Abstract available
   
   
   
7. VAN GULCK E, Pardons M, Nijs E, Verheyen N, et al
   Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity".
   Antimicrob Agents Chemother. 2024 Jul 2:e0081924. doi: 10.1128/aac.00819.
   PubMed    
   
   
   
8. MATTHEWS RP, Liu Y, Matthews C, Butterfield KL, et al
   Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults.
   Antimicrob Agents Chemother. 2024 Jul 2:e0046424. doi: 10.1128/aac.00464.
   PubMed     Abstract available
   
   
   June 2024
9. DIAMOND TL, Goh SL, Ngo W, Rodriguez S, et al
   No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.
   Antimicrob Agents Chemother. 2024 Jun 12:e0033424. doi: 10.1128/aac.00334.
   PubMed     Abstract available
   
   
   
10. MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
    How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
    PubMed     Abstract available
    
    
    
11. RAINES SLM, Falcinelli SD, Peterson JJ, Van Gulck E, et al
    Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets.
    Antimicrob Agents Chemother. 2024 Jun 3:e0020124. doi: 10.1128/aac.00201.
    PubMed     Abstract available
    
    
    May 2024
12. PANJASAWATWONG N, Avihingsanon A, Menetrey C, Ribeiro I, et al
    Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment.
    Antimicrob Agents Chemother. 2024 May 20:e0000824. doi: 10.1128/aac.00008.
    PubMed     Abstract available
    
    
    
13. BECKEN B, Dousa KM, Johnson JL, Holland SM, et al
    Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child.
    Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319.
    PubMed     Abstract available
    
    
    
14. HAN K, Patel P, McCallister S, Rinehart AR, et al
    Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
    Antimicrob Agents Chemother. 2024 May 6:e0147523. doi: 10.1128/aac.01475.
    PubMed     Abstract available
    
    
    April 2024
15. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    PubMed     Abstract available
    
    
    
16. CHANDASANA H, Singh R, Adkison K, Ait-Khaled M, et al
    Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Antimicrob Agents Chemother. 2024 Apr 8:e0150423. doi: 10.1128/aac.01504.
    PubMed     Abstract available
    
    
    March 2024
17. COSSU MV, D'Avolio A, Gervasoni C, Giacomelli A, et al
    Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Antimicrob Agents Chemother. 2024 Mar 27:e0017524. doi: 10.1128/aac.00175.
    PubMed    
    
    
    
18. HAN K
    Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Antimicrob Agents Chemother. 2024 Mar 27:e0020424. doi: 10.1128/aac.00204.
    PubMed    
    
    
    
19. WANG C, Yu X, Ke Y, Fu Y, et al
    Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
    Antimicrob Agents Chemother. 2024 Mar 14:e0166823. doi: 10.1128/aac.01668.
    PubMed     Abstract available
    
    
    
20. JOGIRAJU V, Weber E, Hindman J, West S, et al
    Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
    Antimicrob Agents Chemother. 2024 Mar 8:e0134423. doi: 10.1128/aac.01344.
    PubMed     Abstract available
    
    
    February 2024
21. MULATO A, Lansdon E, Aoyama R, Voigt J, et al
    Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability.
    Antimicrob Agents Chemother. 2024 Feb 21:e0137323. doi: 10.1128/aac.01373.
    PubMed     Abstract available
    
    
    
22. HORVATH RM, Brumme ZL, Sadowski I
    Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting "block and lock" treatment strategies.
    Antimicrob Agents Chemother. 2024 Feb 6:e0107223. doi: 10.1128/aac.01072.
    PubMed     Abstract available
    
    
    December 2023
23. ALI AM, P Solans B, Hesseling AC, Winckler J, et al
    Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2023 Dec 19:e0079423. doi: 10.1128/aac.00794.
    PubMed     Abstract available
    
    
    
24. ABDALLA S, Compagnucci A, Riault Y, Chan MK, et al
    Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
    Antimicrob Agents Chemother. 2023 Dec 11:e0100423. doi: 10.1128/aac.01004.
    PubMed     Abstract available
    
    
    
25. HAN K, Gevorkyan H, Sadik Shaik J, Crauwels H, et al
    Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
    Antimicrob Agents Chemother. 2023 Dec 1:e0078123. doi: 10.1128/aac.00781.
    PubMed     Abstract available
    
    
    October 2023
26. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
    Antimicrob Agents Chemother. 2023 Oct 26:e0073723. doi: 10.1128/aac.00737.
    PubMed     Abstract available
    
    
    
27. VAN GULCK E, Pardons M, Nijs E, Verheyen N, et al
    A truncated HIV Tat demonstrates potent and specific latency reversal activity.
    Antimicrob Agents Chemother. 2023 Oct 24:e0041723. doi: 10.1128/aac.00417.
    PubMed     Abstract available
    
    
    
28. KENGO A, Nabisere R, Gausi K, Musaazi J, et al
    Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043023. doi: 10.1128/aac.00430.
    PubMed     Abstract available
    
    
    
29. KENGO A, Gausi K, Nabisere R, Musaazi J, et al
    Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043123. doi: 10.1128/aac.00431.
    PubMed     Abstract available
    
    
    June 2023
30. BONNARD D, Le Rouzic E, Singer MR, Yu Z, et al
    Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase.
    Antimicrob Agents Chemother. 2023 Jun 13:e0046223. doi: 10.1128/aac.00462.
    PubMed     Abstract available
    
    
    May 2023
31. HUANG T, Cai J, Wang P, Zhou J, et al
    Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR.
    Antimicrob Agents Chemother. 2023 May 22:e0006723. doi: 10.1128/aac.00067.
    PubMed     Abstract available
    
    
    
32. HAO X, Ni J, Zhao D, Zhang W, et al
    No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
    Antimicrob Agents Chemother. 2023 May 1:e0121922. doi: 10.1128/aac.01219.
    PubMed     Abstract available
    
    
    April 2023
33. BERTRAND J, Barrail-Tran A, Fayette L, Savic R, et al
    Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
    Antimicrob Agents Chemother. 2023 Apr 26:e0233918. doi: 10.1128/aac.02339.
    PubMed     Abstract available
    
    
    
34. ELGAMMAL Y, Salama EA, Seleem MN
    Atazanavir Resensitizes Candida auris to Azoles.
    Antimicrob Agents Chemother. 2023 Apr 24:e0163122. doi: 10.1128/aac.01631.
    PubMed     Abstract available
    
    
    
35. XIAO MA, Cleyle J, Yoo S, Forrest M, et al
    The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Antimicrob Agents Chemother. 2023 Apr 18:e0138622. doi: 10.1128/aac.01386.
    PubMed     Abstract available
    
    
    
36. WANG C, Huang H, Mallon K, Valera L, et al
    Antiviral Properties of HIV-1 Capsid Inhibitor GSK878.
    Antimicrob Agents Chemother. 2023 Apr 11:e0169422. doi: 10.1128/aac.01694.
    PubMed     Abstract available
    
    
    March 2023
37. MARZINKE MA, Fogel JM, Wang Z, Piwowar-Manning E, et al
    Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Antimicrob Agents Chemother. 2023 Mar 30:e0005323. doi: 10.1128/aac.00053.
    PubMed     Abstract available
    
    
    
38. TIETJEN I, Schonhofer C, Sciorillo A, Naidu ME, et al
    The Natural Stilbenoid (-)-Hopeaphenol Inhibits HIV Transcription by Targeting Both PKC and NF-kappaB Signaling and Cyclin-Dependent Kinase 9.
    Antimicrob Agents Chemother. 2023 Mar 28:e0160022. doi: 10.1128/aac.01600.
    PubMed     Abstract available
    
    
    
39. HONG H, Aslam-Mir U, Kajubi R, Wallender E, et al
    Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
    Antimicrob Agents Chemother. 2023 Mar 14:e0142722. doi: 10.1128/aac.01427.
    PubMed     Abstract available
    
    
    February 2023
40. UNDERWOOD M, Horton J, Nangle K, Hopking J, et al
    Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Rever
    Antimicrob Agents Chemother. 2023 Feb 16:e0032622. doi: 10.1128/aac.00326.
    PubMed    
    
    
    
41. CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al
    Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426.
    PubMed     Abstract available
    
    
    January 2023
42. JARRETT RT, van der Heijden Y, Shotwell MS, Chihota V, et al
    High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
    Antimicrob Agents Chemother. 2023 Jan 9:e0129722. doi: 10.1128/aac.01297.
    PubMed     Abstract available
    
    
    
43. BANDA CG, Nkosi D, Allen E, Workman L, et al
    Erratum for Banda et al., "Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV".
    Antimicrob Agents Chemother. 2023 Jan 5:e0156222. doi: 10.1128/aac.01562.
    PubMed    
    
    
    November 2022
44. BANDA CG, Nkosi D, Allen E, Workman L, et al
    Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
    Antimicrob Agents Chemother. 2022 Nov 14:e0058422. doi: 10.1128/aac.00584.
    PubMed     Abstract available
    
    
    
45. BHAVNANI SM, Trang M, Griffith DC, Lomovskaya O, et al
    Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Antimicrob Agents Chemother. 2022 Nov 14:e0213021. doi: 10.1128/aac.02130.
    PubMed     Abstract available
    
    
    
46. MATTHEWS RP, Cao Y, Patel M, Weissler VL, et al
    Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency.
    Antimicrob Agents Chemother. 2022 Nov 8:e0093122. doi: 10.1128/aac.00931.
    PubMed     Abstract available
    
    
    October 2022
47. HO K, Dominguez-Islas C, Szydlo D, Edick S, et al
    MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine Gel.
    Antimicrob Agents Chemother. 2022 Oct 18:e0081622. doi: 10.1128/aac.00816.
    PubMed     Abstract available
    
    
    September 2022
48. LUTERBACH CL, Qiu H, Hanafin PO, Sharma R, et al
    A Systems-Based Analysis of Mono- and Combination Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.
    Antimicrob Agents Chemother. 2022 Sep 20:e0059122. doi: 10.1128/aac.00591.
    PubMed     Abstract available
    
    
    
49. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
    Antimicrob Agents Chemother. 2022 Sep 7:e0227721. doi: 10.1128/aac.02277.
    PubMed     Abstract available
    
    
    August 2022
50. PHAM MM, Podany AT, Mwelase N, Supparatpinyo K, et al
    Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrob Agents Chemother. 2022 Aug 9:e0238521. doi: 10.1128/aac.02385.
    PubMed     Abstract available
    
    
    July 2022
51. DEVANATHAN AS, White NR, Desyaterik Y, De la Cruz G, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates.
    Antimicrob Agents Chemother. 2022 Jul 20:e0060922. doi: 10.1128/aac.00609.
    PubMed     Abstract available
    
    
    
52. MTSHALI S, Jacobs BA
    A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
    Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
    PubMed     Abstract available
    
    
    May 2022
53. KAWUMA AN, Wasmann RE, Dooley KE, Boffito M, et al
    Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
    Antimicrob Agents Chemother. 2022 May 23:e0021522. doi: 10.1128/aac.00215.
    PubMed     Abstract available
    
    
    
54. DE NICOLO A, Calcagno A, Motta I, De Vivo E, et al
    The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    Antimicrob Agents Chemother. 2022 May 18:e0013622. doi: 10.1128/aac.00136.
    PubMed     Abstract available
    
    
    
55. DIAMOND TL, Ngo W, Xu M, Goh SL, et al
    Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
    Antimicrob Agents Chemother. 2022 May 12:e0013322. doi: 10.1128/aac.00133.
    PubMed     Abstract available
    
    
    
56. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
    PubMed     Abstract available
    
    
    
57. GARTLAND M, Cahn P, DeJesus E, Diaz RS, et al
    Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Antimicrob Agents Chemother. 2022 May 3:e0175121. doi: 10.1128/aac.01751.
    PubMed     Abstract available
    
    
    
58. LAI MT, Feng M, Xu M, Ngo W, et al
    Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022 May 2:e0222321. doi: 10.1128/aac.02223.
    PubMed     Abstract available
    
    
    April 2022
59. ACOSTA RK, D'Antoni ML, Mulato A, Yant SR, et al
    Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
    Antimicrob Agents Chemother. 2022 Apr 7:e0203821. doi: 10.1128/aac.02038.
    PubMed     Abstract available
    
    
    March 2022
60. SONG N, Zhou X, Li D, Li X, et al
    A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.
    Antimicrob Agents Chemother. 2022 Mar 28:e0210521. doi: 10.1128/aac.02105.
    PubMed     Abstract available
    
    
    
61. MOORE K, Thakkar N, Magee M, Sevinsky H, et al
    Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Antimicrob Agents Chemother. 2022 Mar 22:e0225121. doi: 10.1128/aac.02251.
    PubMed     Abstract available
    
    
    
62. DIDE-AGOSSOU C, Bauman AA, Ramey ME, Rossmassler K, et al
    Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
    Antimicrob Agents Chemother. 2022 Mar 21:e0231021. doi: 10.1128/aac.02310.
    PubMed     Abstract available
    
    
    
63. WALLACE J, Gonzalez H, Rajan R, Narasipura SD, et al
    Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages.
    Antimicrob Agents Chemother. 2022 Mar 16:e0194121. doi: 10.1128/aac.01941.
    PubMed     Abstract available
    
    
    
64. MWANGI JN, Gilliland WM Jr, White N, Sykes C, et al
    Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence.
    Antimicrob Agents Chemother. 2022 Mar 10:e0217621. doi: 10.1128/aac.02176.
    PubMed     Abstract available
    
    
    February 2022
65. HAN K, Wannamaker P, Lu H, Zhu B, et al
    Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
    Antimicrob Agents Chemother. 2022 Feb 7:AAC0205721. doi: 10.1128/AAC.02057.
    PubMed     Abstract available
    
    
    January 2022
66. JEFFREY JL, St Clair M, Wang P, Wang C, et al
    Impact of Integrase Sequences From HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0170221. doi: 10.1128/AAC.01702.
    PubMed     Abstract available
    
    
    
67. AMANO M, Yedidi RS, Salcedo-Gomez PM, Hayashi H, et al
    Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors In Vitro.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0171521. doi: 10.1128/AAC.01715.
    PubMed     Abstract available
    
    
    December 2021
68. LAI PC, Chen CH, Jeng LB, Yu TM, et al
    Grazoprevir/Elbasvir treatment in liver or kidney transplant recipients with genotype-1b hepatitis C virus infection.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0200321. doi: 10.1128/AAC.02003.
    PubMed     Abstract available
    
    
    
69. AGUIAR-ALVES F, Le HN, Tran VG, Gras E, et al
    Anti-virulence Bispecific Monoclonal Antibody Mediated Protection Against Pseudomonas aeruginosa Ventilator-Associated Pneumonia in a Rabbit Model.
    Antimicrob Agents Chemother. 2021 Dec 13:AAC0202221. doi: 10.1128/AAC.02022.
    PubMed     Abstract available
    
    
    
70. LOMBAARD J, Ssali F, Thanyawee P, Fourie J, et al
    Long-term safety, tolerability and antiviral activity of rilpivirine in antiretroviral-naive adolescents living with HIV-1, aged 12 to less than 18 years: Week 240 findings of a phase 2, open-label study, PAINT.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0091621. doi: 10.1128/AAC.00916.
    PubMed     Abstract available
    
    
    November 2021
71. POON R, Basuino L, Satishkumar N, Chatterjee A, et al
    Loss of GdpP function in Staphylococcus aureus leads to beta-lactam tolerance and enhanced evolution of beta-lactam resistance.
    Antimicrob Agents Chemother. 2021 Nov 29:AAC0143121. doi: 10.1128/AAC.01431.
    PubMed     Abstract available
    
    
    
72. DICKER I, Jeffrey JL, Protack T, Lin Z, et al
    GSK3640254 Is a Novel HIV-1 Maturation Inhibitor With an Optimized Virology Profile.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0187621. doi: 10.1128/AAC.01876.
    PubMed     Abstract available
    
    
    
73. ZHANG CX, Love MS, McNamara CW, Chi V, et al
    Pharmacokinetics and pharmacodynamics of clofazimine for treatment of cryptosporidiosis.
    Antimicrob Agents Chemother. 2021 Nov 8:AAC0156021. doi: 10.1128/AAC.01560.
    PubMed     Abstract available
    
    
    
74. BOYER PL, Rehm CA, Sneller MC, Mican J, et al
    A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.
    Antimicrob Agents Chemother. 2021 Nov 1:AAC0150021. doi: 10.1128/AAC.01500.
    PubMed     Abstract available
    
    
    October 2021
75. VAVRO C, Ruel T, Wiznia A, Montanez N, et al
    Emergence of Resistance in HIV-1 Integrase With Dolutegravir Treatment in a Pediatric Population From the IMPAACT P1093 Study.
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164521. doi: 10.1128/AAC.01645.
    PubMed     Abstract available
    
    
    
76. UNDERWOOD M, Horton J, Nangle K, Hopking J, et al
    Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the D
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164321. doi: 10.1128/AAC.01643.
    PubMed     Abstract available
    
    
    
77. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
    Mutations in the HIV-1 3'-polypurine tract can confer dolutegravir resistance.
    Antimicrob Agents Chemother. 2021 Oct 11:AAC0102721. doi: 10.1128/AAC.01027.
    PubMed     Abstract available
    
    
    September 2021
78. ASANTE-APPIAH E, Lai J, Wan H, Yang D, et al
    Impact of HIV-1 Resistance-associated Mutations on Susceptibility to Doravirine: Analysis of Real-world Clinical Isolates.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0121621. doi: 10.1128/AAC.01216.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.